MedTrace Logo

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

NCT05479487 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2022-07-29

No results posted yet for this study

Summary

This study is a Phase II randomized, open label, controlled, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma (including patients previous treated with a PARP inhibitor).

Conditions

  • Relapsed Ovarian Cancer

Interventions

DRUG

Fluzoparib+Apatinib

Fluzoparib 100mg bid+ Apatinib 375mg qd

DRUG

Fluzoparib Monotherapy

Fluzoparib 150mg bid

Sponsors & Collaborators

  • Xiaohua Wu MD

    lead OTHER

Principal Investigators

  • Xiaohua Wu, Ph.D., MD · Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai 200032, China.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-11-01
Completion
2026-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05479487 on ClinicalTrials.gov